• About us
• Contact

Advertisement

Organisation › Details

IO Biotech (Group)

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform. The T-win® platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. IO Biotech is advancing in clinical studies its lead immuno-oncology candidate, IO102-IO103, targeting IDO and PD-L1, and through clinical and preclinical development its other pipeline candidates. IO Biotech is headquartered in Copenhagen, Denmark. *

 

	Start	2014-12-01 splitoff
	Predecessor	Herlev University Hospital
	Industry	T-win® technology
	Industry 2	cancer vaccine
	Person	Zocca, Mai-Britt (IO Biotech ApS 201601 CEO + Founder)
	Region	København (Copenhagen)
	Country	Denmark
	Street	3 Ole Maaløes Vej COBIS
	City	2200 København N
	Tel	+45-21-947856
		Address record changed: 2024-04-17
Basic data	Employees	C: 51 to 100 (2023-12-31)
	Currency	USD
	Profit	-86,083,000 (2023-12-31)
	Cash	143,193,000 (2023-12-31)
		* Document for »About Section«: IO Biotech, Inc.. (11/9/21). "Press Release: IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares". Wilmington, DE.
		Record changed: 2024-04-17

Advertisement

More documents for IO Biotech (Group)

• [1] IO Biotech, Inc.. (8/7/23). "Press Release: IO Biotech, Inc. Announces $75 Million Private Placement Financing". New York, NY....
• [2] IO Biotech, Inc.. (6/1/23). "Press Release: IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead". New York, NY....
• [3] IO Biotech, Inc.. (11/9/21). "Press Release: IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares". Wilmington, DE....
• [4] IO Biotech, Inc.. (11/4/21). "Press Release: IO Biotech, Inc. Announces Pricing of Initial Public Offering". Wilmington, DE....
• [5] IO Biotech ApS. (7/5/21). "Press Release: IO Biotech Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer". Copenhagen....
• [6] IO Biotech ApS. (1/13/21). "Press Release: IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology". Copenhagen....
• [7] IO Biotech ApS. (12/15/20). "Press Release: The Food and Drug Administration (FDA) Grants IO Biotech Breakthrough Therapy Designation for IO102 and IO103 in Combination with anti-PD-1 in Unresectable/Metastatic Melanoma". Copenhagen....
• [8] Valo Therapeutics Ltd.. (6/8/20). "Press Release: Valo Therapeutics Announces Board Appointment of Dr Mai-Britt Zocca". Oxford & Helsinki....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.